Cargando…
Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy
Biological vesicles, containing genetic materials and proteins of the original cells, are usually used for local or systemic communications among cells. Currently, studies on biological vesicles as therapeutic strategies or drug delivery carriers mainly focus on exogenously generated biological vesi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839880/ https://www.ncbi.nlm.nih.gov/pubmed/36424135 http://dx.doi.org/10.1002/advs.202204178 |
_version_ | 1784869540580032512 |
---|---|
author | Kong, Li Yang, Conglian Zhang, Zhiping |
author_facet | Kong, Li Yang, Conglian Zhang, Zhiping |
author_sort | Kong, Li |
collection | PubMed |
description | Biological vesicles, containing genetic materials and proteins of the original cells, are usually used for local or systemic communications among cells. Currently, studies on biological vesicles as therapeutic strategies or drug delivery carriers mainly focus on exogenously generated biological vesicles. However, the limitations of yield and purity caused by the complex purification process still hinder their clinical transformation. Recently, it has been reported that living organisms, including cells and bacteria, can produce functional/therapeutic biological vesicles within body automatically. Therefore, using organisms to produce endogenous biological vesicles in body as drug/bio‐information delivery carriers has become a potential therapeutic strategy. In this review, the current development status and application prospects of in situ organism‐produced biological vesicles are introduced. The advantages and effects of this endogenous biological vesicles‐based strategy in drug delivery and disease treatments are analyzed. According to the type of endogenous biological vesicles, they are divided into four categories: exosomes, platelet‐derived microparticles, apoptotic bodies, and bacteria‐released outer membrane vesicles. And finally, the shortcomings of current research and future development are analyzed. This review is believed to open up the application of endogenous biological vesicles in the field of biomedicine and shed light on current research. |
format | Online Article Text |
id | pubmed-9839880 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98398802023-01-18 Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy Kong, Li Yang, Conglian Zhang, Zhiping Adv Sci (Weinh) Reviews Biological vesicles, containing genetic materials and proteins of the original cells, are usually used for local or systemic communications among cells. Currently, studies on biological vesicles as therapeutic strategies or drug delivery carriers mainly focus on exogenously generated biological vesicles. However, the limitations of yield and purity caused by the complex purification process still hinder their clinical transformation. Recently, it has been reported that living organisms, including cells and bacteria, can produce functional/therapeutic biological vesicles within body automatically. Therefore, using organisms to produce endogenous biological vesicles in body as drug/bio‐information delivery carriers has become a potential therapeutic strategy. In this review, the current development status and application prospects of in situ organism‐produced biological vesicles are introduced. The advantages and effects of this endogenous biological vesicles‐based strategy in drug delivery and disease treatments are analyzed. According to the type of endogenous biological vesicles, they are divided into four categories: exosomes, platelet‐derived microparticles, apoptotic bodies, and bacteria‐released outer membrane vesicles. And finally, the shortcomings of current research and future development are analyzed. This review is believed to open up the application of endogenous biological vesicles in the field of biomedicine and shed light on current research. John Wiley and Sons Inc. 2022-11-24 /pmc/articles/PMC9839880/ /pubmed/36424135 http://dx.doi.org/10.1002/advs.202204178 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Kong, Li Yang, Conglian Zhang, Zhiping Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy |
title | Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy |
title_full | Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy |
title_fullStr | Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy |
title_full_unstemmed | Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy |
title_short | Organism‐Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy |
title_sort | organism‐generated biological vesicles in situ: an emerging drug delivery strategy |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839880/ https://www.ncbi.nlm.nih.gov/pubmed/36424135 http://dx.doi.org/10.1002/advs.202204178 |
work_keys_str_mv | AT kongli organismgeneratedbiologicalvesiclesinsituanemergingdrugdeliverystrategy AT yangconglian organismgeneratedbiologicalvesiclesinsituanemergingdrugdeliverystrategy AT zhangzhiping organismgeneratedbiologicalvesiclesinsituanemergingdrugdeliverystrategy |